UPPSALA, Sweden--(BUSINESS WIRE)--Regulatory News: At today’s Capital Markets Day, Orexo (STO:ORX) announces that – following a successful restructuring – Orexo is now sharpening focus further on development and commercializing own products based on its proprietary drug-delivery technologies applied to well-known substances. The switch from relying solely on partners to commercialize the Company’s innovations entails substantially higher control of the value created, and the chosen product development focus is associated with reduced risks, shorter lead-times and thus lower development costs compared to conventional drug-discovery efforts.
